Restructured Melinta now wants to buy fellow antibiotic maker Tetraphase; TA Associates mulls $500M deal for a stake in CDMO
→ Yet another buyer has emerged in what is shaping up to be a bidding war for Tetraphase and its marketed antibiotic. Melinta — a fellow antibiotics maker that’s freshly restructured under Chapter 11 and now privately owned by Deerfield — is offering to buy it all for $27 million, more than double the original offer by AcelRx that the Tetraphase board had recommended back in March. Since then, La Jolla has also proposed a $22 million deal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.